EUVIMEDEUVIMED entdecken
Open Access

Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice—Lessons Learned from a State Underrepresented in Clinical Psychedelic Research

Amanda Husein, Madalynn Traylor, M Frances Vest, Bo Jarrett Wood, Madison Brogan, Alfred Thomas, Shawn McNeil, Mohammad A N Bhuiyan, Peter Hendricks, John R Kelly, Andrew Gribben, Mohammed M Al-Qahtani und 4 weitere

Psychedelic Medicine · 01.09.2026 · 4 (3) · 161-168

DOI: 10.1177/28314425251381806 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psychedelic Medicine, online erschienen am 19.12.2025. Verfasst von Amanda Husein und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Medicine, School of Medicine, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Schumpert Chair Endowment in Neurobiology, Louisiana Addiction Research Center, Department of Psychiatry and Behavioral Medicine at Louisiana State University Health Sciences Center Shreveport.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Psilocybin has been granted breakthrough therapy status in the United States, speeding its advancement from research to clinical care. Due to the controversial nature of psilocybin, psychiatrists may not be fully prepared to incorporate it into clinical practice. The current study aimed to evaluate the opinions toward psilocybin among practicing psychiatrists in Louisiana. Louisiana serves as a representative state, modeling other areas with limited exposure to psychedelic research.

Methods

A 30-question survey was distributed via mail and digital newsletter to all registered Louisiana psychiatrists. The survey consisted of demographic questions and questions pertaining to how strongly respondents agreed or disagreed with statements about psilocybin and psychedelics on a five-point Likert scale. The statements aimed to assess knowledge and exposure to psilocybin including opinions on research and legalization, safety and addiction potential, medical use, and potential benefits and usages.

Results

Forty-nine responses were recorded. Eighty-two percent of participants reported having “some knowledge” of psilocybin. Eighty-six percent believed psilocybin should be researched for medicinal value, and 71% would prescribe psilocybin if it were proven beneficial for their patient’s illness. Fifty-seven percent believed it should be considered a first-line treatment for certain conditions, while 73% believed it should be used only after exhausting all other treatment modalities. The study had an overall 10.5% response rate, potentially limiting the generalizability of the findings.

Conclusion

Louisiana psychiatrists in our sample appear open to integrating psilocybin into their practice if there is strong regulatory support. Psilocybin research is rapidly expanding and will soon reach Louisiana and other states with a limited history of psychedelic clinical research. These findings warrant the development of an educational program on psychedelics to arm psychiatrists and patients with the knowledge to make the most informed decisions.

Schlagwörter

Stichwörter der Autor:innen

Louisianapsilocybinpsychedelicspsychiatristssurvey

Autor:innen und Institutionen

  • Department of Psychiatry and Behavioral Medicine, School of Medicine, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
  • Louisiana Addiction Research Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
  • Department of Pharmacology, Toxicology & Neuroscience, School of Graduate Studies, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
  • Division of Clinical Informatics, Department of Medicine, School of Medicine, Louisiana State University Health, Shreveport, Louisiana, USA.
  • Department of Psychiatry, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Tallaght University Hospital, Dublin, Ireland.

ORCID-Profile: Kevin S Murnane

Förderung

  • Schumpert Chair Endowment in Neurobiology
  • Louisiana Addiction Research Center
  • Department of Psychiatry and Behavioral Medicine at Louisiana State University Health Sciences Center Shreveport

Zitieren

APA

Husein, A., Traylor, M., Vest, M. F., Wood, B. J., Brogan, M., Thomas, A., McNeil, S., Bhuiyan, M. A. N., Hendricks, P., Kelly, J. R., Gribben, A., Al-Qahtani, M. M., Keys, K., Edinoff, A. N., Patterson, J. C., & Murnane, K. S. (2026). Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice—Lessons Learned from a State Underrepresented in Clinical Psychedelic Research. Psychedelic Medicine, 4(3), 161-168. https://doi.org/10.1177/28314425251381806

Vancouver

Husein A, Traylor M, Vest MF, Wood BJ, Brogan M, Thomas A, et al. Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice—Lessons Learned from a State Underrepresented in Clinical Psychedelic Research. Psychedelic Medicine. 2026;4(3):161-168. doi:10.1177/28314425251381806

BibTeX
@article{Husein2026,
  author = {Husein, Amanda and Traylor, Madalynn and Vest, M Frances and Wood, Bo Jarrett and Brogan, Madison and Thomas, Alfred and McNeil, Shawn and Bhuiyan, Mohammad A N and Hendricks, Peter and Kelly, John R and Gribben, Andrew and Al-Qahtani, Mohammed M and Keys, Kelsea and Edinoff, Amber N and Patterson, James C and Murnane, Kevin S},
  title = {Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice—Lessons Learned from a State Underrepresented in Clinical Psychedelic Research},
  journal = {Psychedelic Medicine},
  year = {2026},
  volume = {4},
  number = {3},
  pages = {161--168},
  doi = {10.1177/28314425251381806}
}
Kostenlos starten →